Immunome (IMNM) Price & Analysis

Compare

324 Followers

IMNM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.15 - $16.73

Previous CloseN/A

Volume79.27K

Average Volume (3M)748.51K

Market Cap

$863.49M

Enterprise Value$545.31M

Total Cash (Recent Filing)$268.04M

Total Debt (Recent Filing)$4.14M

Price to Earnings (P/E)―

Beta1.67

Next Earnings

Nov 17, 2025

EPS Estimate

-0.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.50

Shares Outstanding87,045,006

10 Day Avg. Volume627,748

30 Day Avg. Volume748,507

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.63

Enterprise Value/Revenue43.32

Enterprise Value/Gross Profit43.32

Enterprise Value/Ebitda-2.90

Forecast

1Y Price Target

$21.89

Price Target Upside115.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Clinical DataVaregacestat has shown increased response rates versus nirogacestat (75% vs. 44%) in a Phase 2 trial.

Financial PositionThe company has a strong cash position with $317.3 million in cash and cash equivalents, providing a cash runway into 2027.

LeadershipThe company is led by the former Seagen team, known for their experience in developing a deep ADC pipeline.

Bears Say

Efficacy ConcernsThere is a risk that varegacestat may show worse-than-expected efficacy or an unexpected safety signal in Phase 3.

Market CompetitionThe desmoid market is considered underappreciated, with evidence from Ogsiveo’s significant sales and a major acquisition in the sector.

Uncertain TimelinesThe company has not guided to a timeline for a data readout from the Ph 1 trial evaluating IM-1021.

Immunome News

Gap downgraded, Ulta upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

6d ago

DAY

Immunome initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of Immunome (IMNM) with an Outperform rating and $18 price target The company is...

6d ago

IMNM

Immunome reports Q2 EPS (50c), consensus (50c)

Reports Q2 revenue $4.01M, consensus $1.02M. As of June 30, 2025, cash, cash equivalents and marketable securities totaled...

22d ago

IMNM

Immunome’s Varegacestat: Promising Phase 3 Prospects and Competitive Edge in Desmoid Tumor Treatment

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Immunome today and set a price target of...

3d ago

IMNM

Immunome’s Promising Pipeline and Financial Stability Justify Buy Rating

Leerink Partners analyst Andrew Berens maintained a Buy rating on Immunome on August 6 and set a price...

20d ago

IMNM

Immunome Advances Cancer Therapy Pipeline Amid Financial Loss

Immunome, Inc. ( ($IMNM) ) has released its Q2 earnings. Here is a breakdown of the information Immunome,...

21d ago

IMNM

Promising Outlook for Immunome’s Varegacestat: Buy Rating Affirmed

TD Cowen analyst Tyler Van Buren has reiterated their bullish stance on IMNM stock, giving a Buy rating...

22d ago

IMNM

Immunome’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Immunome today and set a price target of...

22d ago

IMNM

Immunome Elects New Directors at Annual Meeting

An announcement from Immunome ( ($IMNM) ) is now available. Immunome, Inc. held its 2025 Annual Meeting of...

3M ago

IMNM

Immunome, Inc. Reports Q1 2025 Financial Results

Immunome, Inc. ( ($IMNM) ) has released its Q1 earnings. Here is a breakdown of the information Immunome,...

3M ago

IMNM

Immunome’s Promising Pipeline and Strong Financial Position Earns Buy Rating

Analyst Andrew Berens from Leerink Partners maintained a Buy rating on Immunome (IMNM – Research Report) and keeping...

4M ago

IMNM

Immunome’s Promising Pipeline and Strategic Advancements Support Buy Rating

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Immunome (IMNM – Research Report) yesterday and set...

4M ago

IMNM

Immunome Expands Share Reserve in Inducement Plan

An update from Immunome ( ($IMNM) ) is now available. On May 8, 2025, Immunome‘s Board of Directors...

4M ago

IMNM

Immunome reports Q1 EPS (52c), consensus (57c)

As of March 31, 2025, cash, cash equivalents and marketable securities totaled $317.3 million. This total includes net...

4M ago

IMNM

IMNM FAQ

What was Immunome’s price range in the past 12 months?

Immunome lowest stock price was $5.15 and its highest was $16.73 in the past 12 months.

What is Immunome’s market cap?

Immunome’s market cap is $863.49M.

When is Immunome’s upcoming earnings report date?

Immunome’s upcoming earnings report date is Nov 17, 2025 which is in 81 days.

How were Immunome’s earnings last quarter?

Immunome released its earnings results on Aug 06, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.517 by $0.017.

Is Immunome overvalued?

According to Wall Street analysts Immunome’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immunome pay dividends?

Immunome does not currently pay dividends.

What is Immunome’s EPS estimate?

Immunome’s EPS estimate is -0.57.

How many shares outstanding does Immunome have?

Immunome has 87,045,006 shares outstanding.

What happened to Immunome’s price movement after its last earnings report?

Immunome reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.517. Following the earnings report the stock price went down -5.641%.

Which hedge fund is a major shareholder of Immunome?

Currently, no hedge funds are holding shares in IMNM

Immunome Stock Smart Score

Outperform

Fundamentals

Return on Equity

-81.20%

Trailing 12-Months

Asset Growth

0.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immunome

Immunome, Inc. (IMNM) is a biotechnology company focused on harnessing the body's immune system to develop transformative therapies targeting cancer and infectious diseases. Utilizing its proprietary discovery engine, Immunome identifies novel antibody therapeutics by analyzing the human immune response, aiming to create innovative solutions that address unmet medical needs.

Immunome (IMNM) Earnings & Revenues

Historic Earnings Reports

IMNM Stock 12 Month Forecast

Average Price Target

$21.89

▲(115.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","22":"$22","39":"$39","13.5":"$13.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,13.5,22,30.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.59,12.698461538461538,14.806923076923077,16.915384615384617,19.023846153846154,21.13230769230769,23.24076923076923,25.349230769230772,27.45769230769231,29.56615384615385,31.674615384615386,33.78307692307692,35.89153846153846,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.59,11.45923076923077,12.32846153846154,13.197692307692307,14.066923076923077,14.936153846153847,15.805384615384614,16.674615384615386,17.543846153846154,18.413076923076922,19.282307692307693,20.15153846153846,21.020769230769233,{"y":21.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.59,10.544615384615385,10.499230769230769,10.453846153846154,10.408461538461538,10.363076923076923,10.317692307692308,10.272307692307692,10.226923076923077,10.181538461538462,10.136153846153846,10.090769230769231,10.045384615384615,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.69,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.18,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.52,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.59,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >